Journal of the American College of Cardiology · 2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.
СтатьяПоддержка NIH: внешняя программаОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Talasaz Azita H, Sadeghipour Parham, Aghakouchakzadeh Maryam, Dreyfus Isaac, Kakavand Hessam, Ariannejad Hamid, Gupta Aakriti, Madhavan Mahesh V, Van Tassell Benjamin W, Jimenez David, Monreal Manuel, Vaduganathan Muthiah, Fanikos John, Dixon Dave L, Piazza Gregory, Parikh Sahil A, Bhatt Deepak L, Lip Gregory Y H, Stone Gregg W, Krumholz Harlan M, Libby Peter, Goldhaber Samuel Z, Bikdeli Behnood
Аннотация
Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.